MET D1228V

CI-VAR-00000413Explore in graph →NP_001120972.1:p.Asp1246ValNM_001127500.3:c.3737A>TCIViC 798

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma2
MET D1228V	Cabozantinib	Predictive	C	Supports Sensitivity Response	4	accepted	EID1864 Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined type I MET (savoli… (full text at CIViC) PMID 27694386 · Bahcall et al., 2016 · Open in CIViC	civic
MET D1228V	Savolitinib	Predictive	C	Supports Resistance	4	accepted	EID1865 Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined type I MET (savoli… (full text at CIViC) PMID 27694386 · Bahcall et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.